Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

132.12 -0.24 (-0.18%)
Streaming Delayed Price Updated: 1:13 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
52 53 Next >
News headline image
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services ↗
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
News headline image
For those who appreciate value investing, NYSE:NVS is a compelling option with its solid fundamentals. ↗
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Why the dividend investor may take a look at NYSE:NVS. ↗
Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) qualifies as a good dividend investing stock. 
Via Chartmill
News headline image
2 Dividend Stocks to Buy and Hold Forever ↗
Via The Motley Fool
News headline image
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
From FN Media Group LLC
Via GlobeNewswire
News headline image
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ↗
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
News headline image
Exploring NYSE:NVS's dividend characteristics. ↗
Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing? 
Via Chartmill
News headline image
Is NYSE:NVS suited for dividend investing? ↗
Uncovering Dividend Opportunities with NOVARTIS AG-SPONSORED ADR (NYSE:NVS). 
Via Chartmill
News headline image
Novartis Reports Q3 Momentum, But Shares Lose Support ↗
Novartis stock slipped Tuesday, despite a solid Q3 performance and an upgraded outlook. 
Via Investor's Business Daily
News headline image
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug ↗
The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval. 
Via Investor's Business Daily
News headline image
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder ↗
Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and consistent safety profile after 24 weeks. 
Via Benzinga
News headline image
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst ↗
Janux Therapeutics reports updated clinical data for JANX007, highlighting significant efficacy, safety, and durability in advanced prostate cancer patients. 
Via Benzinga
News headline image
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program ↗
PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up to $2.9 billion, including milestones and royalties. 
Via Benzinga
News headline image
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone ↗
The deal focuses on the company's treatment for Huntington's disease. 
Via Investor's Business Daily
News headline image
Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline ↗
Novartis increases mid-term sales growth forecast to 6% CAGR for 2023-2028, citing robust growth drivers, upcoming launches, and a promising innovation pipeline. 
Via Benzinga
News headline image
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details ↗
Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will receive $150 million upfront and eligible to receive up to approximately $2.3... 
Via Benzinga
News headline image
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
News headline image
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
News headline image
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy ↗
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities. 
Via Benzinga
News headline image
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript ↗
NVS earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook ↗
Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024. 
Via Benzinga
Topics Earnings
News headline image
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis ↗
The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases. 
Via Investor's Business Daily
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
Via AB Newswire
Topics Artificial Intelligence
News headline image
Why Is Monte Rosa Therapeutics Stock Surging On Monday? ↗
Monte Rosa Therapeutics stock rises as it announces a global licensing deal with Novartis to advance MRT-6160 for immune conditions. 
Via Benzinga
News headline image
3 Absurdly Cheap Stocks That Pay High Dividends ↗
These stocks are trading at less than 15 times their expected future profits. 
Via The Motley Fool
News headline image
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent ↗
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,... 
Via Benzinga
News headline image
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer ↗
Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a significant reduction in cancer recurrence in a Phase 3 trial. European... 
Via Benzinga
News headline image
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move ↗
Novartis is taking a more calculated and strategic approach to its growth. 
Via The Motley Fool
News headline image
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch ↗
William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.